Covid-19 could throw final hurdle into AbbVie and Allergan’s massive merger
You can add AbbVie and Allergan’s $63 billion merger to the list of plans potentially disrupted by Covid-19.
The Federal Trade Commission said that it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
